| Literature DB >> 26299335 |
Jacob S Thomas1, Fairooz Kabbinavar2.
Abstract
Treatment of metastatic renal cell carcinoma (mRCC) has changed dramatically in the past 10 years, largely due to advances in understanding of tumor biology. A number of targeted therapies have been shown to improve progression free survival and overall survival as compared to nonspecific immunotherapy. Despite the success of targeted therapies, they have not produced durable responses that have been seen historically with immunotherapy such as IL-2 (interleukin 2) and IFN-α (interferon). The promise of durable responses has caused some to shift research focus from targeted therapies to novel immunotherapies. This article reviews the literature behind the current targeted therapies and describes several novel approaches to immunotherapy that are in various phases of development.Entities:
Keywords: Carcinoma; Dendritic cells; Immunotherapy; Programmed cell death 1 receptor; Renal cell
Mesh：
Substances：
Year: 2015 PMID： 26299335 DOI： 10.1016/j.critrevonc.2015.07.009
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312